• Je něco špatně v tomto záznamu ?

Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial

K. Kotulska, DJ. Kwiatkowski, P. Curatolo, B. Weschke, K. Riney, F. Jansen, M. Feucht, P. Krsek, R. Nabbout, AC. Jansen, K. Wojdan, K. Sijko, J. Głowacka-Walas, J. Borkowska, K. Sadowski, D. Domańska-Pakieła, R. Moavero, C. Hertzberg, H. Hulshof,...

. 2021 ; 89 (2) : 304-314. [pub] 20201127

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21011515

OBJECTIVE: Epilepsy develops in 70 to 90% of children with tuberous sclerosis complex (TSC) and is often resistant to medication. Recently, the concept of preventive antiepileptic treatment to modify the natural history of epilepsy has been proposed. EPISTOP was a clinical trial designed to compare preventive versus conventional antiepileptic treatment in TSC infants. METHODS: In this multicenter study, 94 infants with TSC without seizure history were followed with monthly video electroencephalography (EEG), and received vigabatrin either as conventional antiepileptic treatment, started after the first electrographic or clinical seizure, or preventively when epileptiform EEG activity before seizures was detected. At 6 sites, subjects were randomly allocated to treatment in a 1:1 ratio in a randomized controlled trial (RCT). At 4 sites, treatment allocation was fixed; this was denoted an open-label trial (OLT). Subjects were followed until 2 years of age. The primary endpoint was the time to first clinical seizure. RESULTS: In 54 subjects, epileptiform EEG abnormalities were identified before seizures. Twenty-seven were included in the RCT and 27 in the OLT. The time to the first clinical seizure was significantly longer with preventive than conventional treatment [RCT: 364 days (95% confidence interval [CI] = 223-535) vs 124 days (95% CI = 33-149); OLT: 426 days (95% CI = 258-628) vs 106 days (95% CI = 11-149)]. At 24 months, our pooled analysis showed preventive treatment reduced the risk of clinical seizures (odds ratio [OR] = 0.21, p = 0.032), drug-resistant epilepsy (OR = 0.23, p = 0.022), and infantile spasms (OR = 0, p < 0.001). No adverse events related to preventive treatment were noted. INTERPRETATION: Preventive treatment with vigabatrin was safe and modified the natural history of seizures in TSC, reducing the risk and severity of epilepsy. ANN NEUROL 2021;89:304-314.

Amsterdam UMC University of Amsterdam Department of Pathology Amsterdam Neuroscience Amsterdam The Netherlands

Brigham and Women's Hospital Harvard Medical School Boston MA USA

Child Neurology and Psychiatry Unit Systems Medicine Department Tor Vergata University Rome Italy

Child Neurology Unit Neuroscience and Neurorehabilitation Department Bambino Gesù Children's Hospital IRCCS Rome Italy

Department of Child Neurology Brain Center University Medical Center Utrecht Utrecht The Netherlands

Department of Child Neurology Charité University Medicine Berlin Berlin Germany

Department of Child Neurology Medical University of Warsaw Warsaw Poland

Department of Development and Regeneration Section Pediatric Neurology University Hospitals KU Leuven Leuven Belgium

Department of Neurology and Epileptology The Children's Memorial Health Institute Warsaw Poland

Department of Pediatric Neurology Reference Centre for Rare Epilepsies Necker Enfants Malades Hospital University Paris Descartes Imagine Institute Paris France

Department of Pediatrics University Hospital Vienna Vienna Austria

Motol University Hospital Charles University Prague 5 Czech Republic

Neurogenetics Research Group Vrije Universiteit Brussel Brussels Belgium

Neurosciences Unit Queensland Children's Hospital South Brisbane QLD Australia

Pediatric Neurology Unit UZ Brussel Brussels Belgium

School of Medicine University of Queensland St Lucia QLD Australia

Transition Technologies Warsaw Poland

Warsaw University of Technology Institute of Heat Engineering Warsaw Poland

Warsaw University of Technology The Faculty of Electronics and Information Technology Warsaw Poland

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21011515
003      
CZ-PrNML
005      
20210507101601.0
007      
ta
008      
210420s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ana.25956 $2 doi
035    __
$a (PubMed)33180985
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kotulska, Katarzyna $u Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland
245    10
$a Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial / $c K. Kotulska, DJ. Kwiatkowski, P. Curatolo, B. Weschke, K. Riney, F. Jansen, M. Feucht, P. Krsek, R. Nabbout, AC. Jansen, K. Wojdan, K. Sijko, J. Głowacka-Walas, J. Borkowska, K. Sadowski, D. Domańska-Pakieła, R. Moavero, C. Hertzberg, H. Hulshof, T. Scholl, B. Benova, E. Aronica, J. de Ridder, L. Lagae, S. Jóźwiak, EPISTOP Investigators
520    9_
$a OBJECTIVE: Epilepsy develops in 70 to 90% of children with tuberous sclerosis complex (TSC) and is often resistant to medication. Recently, the concept of preventive antiepileptic treatment to modify the natural history of epilepsy has been proposed. EPISTOP was a clinical trial designed to compare preventive versus conventional antiepileptic treatment in TSC infants. METHODS: In this multicenter study, 94 infants with TSC without seizure history were followed with monthly video electroencephalography (EEG), and received vigabatrin either as conventional antiepileptic treatment, started after the first electrographic or clinical seizure, or preventively when epileptiform EEG activity before seizures was detected. At 6 sites, subjects were randomly allocated to treatment in a 1:1 ratio in a randomized controlled trial (RCT). At 4 sites, treatment allocation was fixed; this was denoted an open-label trial (OLT). Subjects were followed until 2 years of age. The primary endpoint was the time to first clinical seizure. RESULTS: In 54 subjects, epileptiform EEG abnormalities were identified before seizures. Twenty-seven were included in the RCT and 27 in the OLT. The time to the first clinical seizure was significantly longer with preventive than conventional treatment [RCT: 364 days (95% confidence interval [CI] = 223-535) vs 124 days (95% CI = 33-149); OLT: 426 days (95% CI = 258-628) vs 106 days (95% CI = 11-149)]. At 24 months, our pooled analysis showed preventive treatment reduced the risk of clinical seizures (odds ratio [OR] = 0.21, p = 0.032), drug-resistant epilepsy (OR = 0.23, p = 0.022), and infantile spasms (OR = 0, p < 0.001). No adverse events related to preventive treatment were noted. INTERPRETATION: Preventive treatment with vigabatrin was safe and modified the natural history of seizures in TSC, reducing the risk and severity of epilepsy. ANN NEUROL 2021;89:304-314.
650    _2
$a antikonvulziva $x terapeutické užití $7 D000927
650    _2
$a refrakterní epilepsie $x prevence a kontrola $7 D000069279
650    _2
$a elektroencefalografie $7 D004569
650    _2
$a epilepsie $x farmakoterapie $x etiologie $x patofyziologie $x prevence a kontrola $7 D004827
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a plošný screening $7 D008403
650    _2
$a záchvaty $x diagnóza $x farmakoterapie $x etiologie $x prevence a kontrola $7 D012640
650    _2
$a křeče u dětí $x prevence a kontrola $7 D013036
650    _2
$a tuberózní skleróza $x komplikace $x patofyziologie $7 D014402
650    _2
$a vigabatrin $x terapeutické užití $7 D020888
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kwiatkowski, David J $u Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Curatolo, Paolo $u Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University, Rome, Italy
700    1_
$a Weschke, Bernhard $u Department of Child Neurology, Charité University Medicine Berlin, Berlin, Germany
700    1_
$a Riney, Kate $u Neurosciences Unit, Queensland Children's Hospital, South Brisbane, QLD, Australia $u School of Medicine, University of Queensland, St Lucia, QLD, Australia
700    1_
$a Jansen, Floor $u Department of Child Neurology, Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands
700    1_
$a Feucht, Martha $u Department of Pediatrics, University Hospital Vienna, Vienna, Austria
700    1_
$a Krsek, Pavel $u Motol University Hospital, Charles University, Prague 5, Czech Republic
700    1_
$a Nabbout, Rima $u Department of Pediatric Neurology, Reference Centre for Rare Epilepsies, Necker- Enfants Malades Hospital, University Paris Descartes, Imagine Institute, Paris, France
700    1_
$a Jansen, Anna C $u Pediatric Neurology Unit-UZ Brussel, Brussels, Belgium $u Neurogenetics Research Group, Vrije Universiteit Brussel, Brussels, Belgium
700    1_
$a Wojdan, Konrad $u Transition Technologies, Warsaw, Poland $u Warsaw University of Technology, Institute of Heat Engineering, Warsaw, Poland
700    1_
$a Sijko, Kamil $u Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland $u Transition Technologies, Warsaw, Poland
700    1_
$a Głowacka-Walas, Jagoda $u Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland $u Warsaw University of Technology, The Faculty of Electronics and Information Technology, Warsaw, Poland
700    1_
$a Borkowska, Julita $u Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland
700    1_
$a Sadowski, Krzysztof $u Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland
700    1_
$a Domańska-Pakieła, Dorota $u Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland
700    1_
$a Moavero, Romina $u Child Neurology Unit, Neuroscience and Neurorehabilitation Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
700    1_
$a Hertzberg, Christoph $u Department of Child Neurology, Charité University Medicine Berlin, Berlin, Germany
700    1_
$a Hulshof, Hanna $u Department of Child Neurology, Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands
700    1_
$a Scholl, Theresa $u Department of Pediatrics, University Hospital Vienna, Vienna, Austria
700    1_
$a Benova, Barbora $u Motol University Hospital, Charles University, Prague 5, Czech Republic
700    1_
$a Aronica, Eleonora $u Amsterdam UMC, University of Amsterdam, Department of (Neuro)Pathology, Amsterdam Neuroscience, Amsterdam, The Netherlands
700    1_
$a de Ridder, Jessie $u Department of Development and Regeneration-Section Pediatric Neurology, University Hospitals KU Leuven, Leuven, Belgium
700    1_
$a Lagae, Lieven $u Department of Development and Regeneration-Section Pediatric Neurology, University Hospitals KU Leuven, Leuven, Belgium
700    1_
$a Jóźwiak, Sergiusz $u Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland $u Department of Child Neurology, Medical University of Warsaw, Warsaw, Poland
710    2_
$a EPISTOP Investigators
773    0_
$w MED00000428 $t Annals of neurology $x 1531-8249 $g Roč. 89, č. 2 (2021), s. 304-314
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33180985 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507101601 $b ABA008
999    __
$a ok $b bmc $g 1650020 $s 1131894
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 89 $c 2 $d 304-314 $e 20201127 $i 1531-8249 $m Annals of neurology $n Ann Neurol $x MED00000428
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace